BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 17145880)

  • 1. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.
    Kahl P; Gullotti L; Heukamp LC; Wolf S; Friedrichs N; Vorreuther R; Solleder G; Bastian PJ; Ellinger J; Metzger E; Schüle R; Buettner R
    Cancer Res; 2006 Dec; 66(23):11341-7. PubMed ID: 17145880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer.
    Heemers HV; Regan KM; Dehm SM; Tindall DJ
    Cancer Res; 2007 Nov; 67(21):10592-9. PubMed ID: 17975004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression.
    Wissmann M; Yin N; Müller JM; Greschik H; Fodor BD; Jenuwein T; Vogler C; Schneider R; Günther T; Buettner R; Metzger E; Schüle R
    Nat Cell Biol; 2007 Mar; 9(3):347-53. PubMed ID: 17277772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate.
    Kinoshita M; Nakagawa T; Shimizu A; Katsuoka Y
    Int J Urol; 2005 Apr; 12(4):390-7. PubMed ID: 15948728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the transcriptional coregulator FHL2 in human breast cancer: a clinicopathologic study.
    Gabriel B; Fischer DC; Orlowska-Volk M; zur Hausen A; Schüle R; Müller JM; Hasenburg A
    J Soc Gynecol Investig; 2006 Jan; 13(1):69-75. PubMed ID: 16378916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease.
    Ricciardelli C; Choong CS; Buchanan G; Vivekanandan S; Neufing P; Stahl J; Marshall VR; Horsfall DJ; Tilley WD
    Prostate; 2005 Apr; 63(1):19-28. PubMed ID: 15378523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
    McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
    Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
    Axlund SD; Lambert JR; Nordeen SK
    Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
    Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
    Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer.
    Mori R; Wang Q; Quek ML; Tarabolous C; Cheung E; Ye W; Groshen S; Hawes D; Togo S; Shimada H; Danenberg KD; Danenberg PV; Pinski JK
    Anticancer Res; 2008; 28(1B):425-30. PubMed ID: 18383880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
    Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
    Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion.
    Björkman M; Östling P; Härmä V; Virtanen J; Mpindi JP; Rantala J; Mirtti T; Vesterinen T; Lundin M; Sankila A; Rannikko A; Kaivanto E; Kohonen P; Kallioniemi O; Nees M
    Oncogene; 2012 Jul; 31(29):3444-56. PubMed ID: 22120715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D.
    Shin S; Janknecht R
    Biochem Biophys Res Commun; 2007 Aug; 359(3):742-6. PubMed ID: 17555712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis.
    Diallo JS; Aldejmah A; Mouhim AF; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F
    BJU Int; 2008 May; 101(10):1302-9. PubMed ID: 18294307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of aryl hydrocarbon receptor activity by four and a half LIM domain 2.
    Kollara A; Brown TJ
    Int J Biochem Cell Biol; 2009 May; 41(5):1182-8. PubMed ID: 19015043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms.
    Brys M; Stawinska M; Foksinski M; Barecki A; Zydek C; Miekos E; Krajewska WM
    Oncol Rep; 2004 Jan; 11(1):219-24. PubMed ID: 14654929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2.
    Nair SS; Guo Z; Mueller JM; Koochekpour S; Qiu Y; Tekmal RR; Schüle R; Kung HJ; Kumar R; Vadlamudi RK
    Mol Endocrinol; 2007 Mar; 21(3):613-24. PubMed ID: 17192406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
    Rosner IL; Ravindranath L; Furusato B; Chen Y; Gao C; Cullen J; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
    Urology; 2007 Dec; 70(6):1225-9. PubMed ID: 18158066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
    Zhigang Z; Wenlu S
    Prostate; 2005 Dec; 65(4):299-305. PubMed ID: 16015594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.